RxDoctor Payments Data

Brenda McCullough

Family · Pampa, TXNPI 1265574370

Payments from drug & device makers

$724in general payments, 2019–2025

Across 42 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$212
  • AbbVie$148
  • Axsome Therapeutics, Inc.$63
  • Novartis$50
  • Boehringer Ingelheim$36
  • AstraZeneca$31
  • plus $185 from 9 others

What the payments were for

  • Food & beverage$724100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$724 in reported general payments places this provider in the 60th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$56,416
Medicare patients
21
Services billed
4,679

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban115$99,522
RybelsusSemaglutide38$81,217
JardianceEmpagliflozin71$79,582
FarxigaDapagliflozin Propanediol87$75,313
OzempicSemaglutide62$63,441
TrulicityDulaglutide39$53,206
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$32,043
MounjaroTirzepatide28$27,780
RexultiBrexpiprazole13$20,229
LinzessLinaclotide26$14,249
Tresiba Flextouch U-100Insulin Degludec23$12,326
JanuviaSitagliptin Phosphate11$11,568
MyrbetriqMirabegron13$8,443
Dexlansoprazole DrDexlansoprazole16$7,552
Gabapentin352$6,191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$36$79,58271 claims
AstraZenecaFarxiga$31$75,31387 claims
GSKTrelegy Ellipta$29$32,04322 claims
Otsuka America Pharmaceutical, Inc.Rexulti$23$20,22913 claims
AbbVieLinzess, Synthroid$148$16,35160 claims
MerckJanuvia$14$11,56811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 15,456 family providers in Texas.

Other family in Pampa

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →